MIAMI--(BUSINESS WIRE)--March 11, 2005--DOR BioPharma, Inc. ("DOR" or the "Company") (AMEX:DOR) announced today the appointment of George A. Robertson, Ph.D. as the Company's Vice President of Research and Development. Dr. Robertson brings to DOR over 20 years of experience in the pharmaceutical, biopharmaceutical and biodefense industries, specializing in process development, manufacturing, validation, QA/QC and vaccine technical operations. Dr. Robertson began his pharmaceutical career at Merck, where he was Manager of the Biological Quality Control Laboratories and Biological Production Technical Services Senior Scientist for the introduction of Merck's Hepatitis A vaccine into GMP production.
Dr. Robertson's unique experience includes Director of Quality Control Operations, Wyeth Vaccines where he headed a 120-person Quality Control operation which included pharmaceutical chemical, biochemical, in vivo, microbiological and environmental testing activities. Previously, Dr. Robertson was Program Director for the BioReliance Corporation's 50,000 square foot vaccine manufacturing facility. During his tenure at the NCI-Frederick Cancer Research & Development Center, he contributed to every stage of the design, construction, commissioning and validation of the pilot biologics production program. Under his leadership, the facility produced over twenty new, bio-pharmaceutical products for clinical use.
